"I guess we can’t expect much until after the Fourth of July 2019....that when we should have the adjuctication results.....I don’t expect much regarding a confirmation by the end of April, or sooner, of completion of all the tests"

I'm not sure if you are commenting on the share price or news of reaching 250+ events and end of dosing. If share price, then yes your prediction is one possibility that is along the rational lines of show me the results before the share price moves. However, that is only one possibility. Share price movement and market cap valuations do not always conform to rational logic. There is a lot of irrational emotion that can take things for a wild ride. Keep in mind that Resverlogix, apabetalone and BETonMACE are still flying under the radar. In my opinion, a $1 billion USD valuation is not unreasonable pre-topline based upon some contemporary comparisons to AMRN and ESPR pre-CVOT top-line. That is twice the current Resverlogix market cap.

As for news of reaching 250+ events and end of dosing.......I asked IR last month "Is end of dosing in BETonMACE considered material information/material development requiring public disclosure? Is reaching 250 adjudicated MACE events in BETonMACE considered material information/material development requiring public disclosure?"

IR replied "It would be our intention to announce when we reach 250+ narrow events which will likely include info relating to end of dosing. Yes we plan to announce when we reach 250+ narrow events."

Sounds like they confirmed that reaching target events and end of dosing is material and will be announced. 

BearDownAZ